Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases

Pamela R. Kushner,1 Matthew A. Cavender,2 and Christian W. Mende3

Individuals with type 2 diabetes are at increased risk of both renal and cardiovascular events. The convergence of type 2 diabetes, chronic kidney disease, and cardiovascular disease, including heart failure, requires management by a multidisciplinary health care team. Primary care clinicians are likely to be the first and most frequent point of contact for individuals with type 2 diabetes who are at high risk of cardiorenal disease and therefore play a pivotal role in early diagnosis, establishment of effective treatment strategies, and coordination of care. This article presents a clinical perspective with multidisciplinary collaboration on a patient case representative of those seen in routine clinical practice. The authors assess reasons why patients may not receive evidence-based care and identify opportunities to initiate therapies that reduce cardiovascular and renal events in the primary care setting.

Both diabetes (present in 13% of adults in the United States, with type 2 diabetes accounting for 90% of these cases) and hypertension (present in 46% of adults in the United States) are independently associated with an increased risk of chronic kidney disease (CKD) and cardiovascular disease (CVD), including both ischemic heart disease and heart failure (HF) (1). Between 2013 and 2016, the estimated prevalence of CKD was 15% in the general U.S. population and substantially higher in people with diabetes or hypertension (37% and 31%, respectively) than in those without these conditions (1). The global prevalence of CVD in people with type 2 diabetes is estimated to be >30% and continues to increase (2). Given that people with type 2 diabetes are twice as likely to develop HF as those without type 2 diabetes (3), increased use of therapies that prevent cardiovascular events is needed.

The heart and kidneys are closely linked, and acute or chronic impairment in one organ can lead to dysfunction in the other (4). The term cardiorenal syndrome (CRS) is used to define the group of disorders that arise from this bidirectional dysfunction of the heart and kidneys (4,5). People with CRS, with or without diabetes, are at increased risk of mortality, hospitalization, and poor health-related quality of life, leading to elevated health care resource utilization (6,7). Furthermore, concomitant type 2 diabetes and CKD or HF increases the risk of adverse outcomes compared with type 2 diabetes alone. People with type 2 diabetes and CKD are at increased risk of major adverse cardiovascular events, HF, and all-cause mortality compared with those with type 2 diabetes alone (8). HF in people with type 2 diabetes has been associated with a higher 5-year absolute and relative risk of death when compared with those with type 2 diabetes but without cardiovascular or renal diagnoses (9).

The convergence of CKD, CVD, and type 2 diabetes poses a unique challenge to health care systems and requires management by a multidisciplinary team of health care practitioners. Here, we discuss the key role that primary care clinicians (PCCs) play in the management and treatment of individuals with type 2 diabetes and cardiorenal diseases. Although individuals with advanced cardiorenal diseases may be managed by cardiologists and/or nephrologists, PCCs often have long-standing relationships with these patients and see them more frequently than do specialists. In addition, PCCs

---

1University of California, Irvine, CA; 2University of North Carolina, Chapel Hill, NC; 3University of California, San Diego, CA

Corresponding author: Pamela R. Kushner, pkushner@hs.uci.edu

https://doi.org/10.2337/cd21-0119

©2022 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
remain crucial for maintenance of basic health needs and support.

**Methods**

Clinical perspectives on a patient case that is representative of those seen in routine clinical practice were gathered from a PCC, a nephrologist, and a cardiologist to assess opportunities for the earlier diagnosis and management of cardiorenal diseases in individuals with type 2 diabetes. The role of PCCs in the treatment and management of individuals with CKD, HF, and type 2 diabetes was also discussed.

**Case Presentation**

An African American woman aged 58 years with type 2 diabetes was also discussed.

**Methods**

Clinical perspectives on a patient case that is representative of those seen in routine clinical practice were gathered from a PCC, a nephrologist, and a cardiologist to assess opportunities for the earlier diagnosis and management of cardiorenal diseases in individuals with type 2 diabetes. The role of PCCs in the treatment and management of individuals with CKD, HF, and type 2 diabetes was also discussed.

**Case Presentation**

An African American woman aged 58 years with type 2 diabetes was also discussed.

**Methods**

Clinical perspectives on a patient case that is representative of those seen in routine clinical practice were gathered from a PCC, a nephrologist, and a cardiologist to assess opportunities for the earlier diagnosis and management of cardiorenal diseases in individuals with type 2 diabetes. The role of PCCs in the treatment and management of individuals with CKD, HF, and type 2 diabetes was also discussed.

**Case Presentation**

An African American woman aged 58 years with type 2 diabetes was also discussed.

**Methods**

Clinical perspectives on a patient case that is representative of those seen in routine clinical practice were gathered from a PCC, a nephrologist, and a cardiologist to assess opportunities for the earlier diagnosis and management of cardiorenal diseases in individuals with type 2 diabetes. The role of PCCs in the treatment and management of individuals with CKD, HF, and type 2 diabetes was also discussed.

**Case Presentation**

An African American woman aged 58 years with type 2 diabetes was also discussed.

**Methods**

Clinical perspectives on a patient case that is representative of those seen in routine clinical practice were gathered from a PCC, a nephrologist, and a cardiologist to assess opportunities for the earlier diagnosis and management of cardiorenal diseases in individuals with type 2 diabetes. The role of PCCs in the treatment and management of individuals with CKD, HF, and type 2 diabetes was also discussed.

**Case Presentation**

An African American woman aged 58 years with type 2 diabetes was also discussed.
eGFR levels monitored twice annually to guide therapy, according to American Diabetes Association (ADA) guidelines (25). Kidney Disease: Improving Global Outcomes (KDIGO) also recommends CKD screening, risk stratification, and treatment for high-risk individuals, including those with hypertension, diabetes, or CVD (26).

For many patients, the first diagnosis of HF is made during a presentation of acute decompensated HF. However, nonspecific signs (edema, swelling, and weight gain) or symptoms (shortness of breath with exertion, fatigue, paroxysmal nocturnal dyspnea, and/or orthopnea) of HF may have been present previously. Because CKD is a risk factor for HF, an earlier diagnosis of CKD
through eGFR and UACR screening in this patient, in addition to her existing diagnoses of hypertension, obesity, and type 2 diabetes, would have led to her being categorized as high risk for HF by her PCC (5,27).

Given this medical history, the patient would have been a candidate for B-type natriuretic peptide (BNP) or NT-proBNP testing, which is available to PCCs at a relatively low cost. Elevated levels (BNP ≥35 pg/mL and NT-proBNP ≥150 pg/mL) may be a sign of subclinical volume overload (28), and testing establishes a baseline for future comparison. When BNP or NT-proBNP levels are found to be elevated, an echocardiogram should be considered to evaluate cardiac function, including systolic and diastolic function, valvular heart disease, and other parameters of myocardial stress or dysfunction (29). Although access to and reimbursement of echocardiography may vary across health care settings and geographical locations, it is widely available throughout the world.

**What Treatment Regimen Should This Patient Have Received?**

Current evidence suggests that the treatment regimen this patient received before hospitalization was not optimized to prevent or delay the progression of cardiorenal diseases. Irrespective of their UACR measurement, patients with hypertension and diabetes should receive renin-angiotensin receptor inhibition with either an ACE inhibitor or an angiotensin receptor blocker; renin-angiotensin-aldosterone system inhibitors should be titrated to the maximal tolerated dose to reach a suggested blood pressure target of <130/80 mmHg (30,31). This target is in line with 2022 ADA guidelines for the management of CVD in type 2 diabetes (32), although an ideal blood pressure goal for patients with hypertension and diabetes has yet to be firmly established from randomized clinical trials. This patient, like many others, received a suboptimal dose of lisinopril, based on current guidelines (33). In addition, her relatively well-controlled glycemic level (A1C 7.1%), eGFR indicative of stage 2 CKD (60 mL/min/1.73 m²), and high BMI (31.2 kg/m²) meant that glipizide treatment was not ideal, given data demonstrating that this class of drug increases the risk of hypoglycemia and weight gain (17). It has also been suggested that treatment with sulfonylureas may exacerbate the risk of HF, although evidence is weak (34,35).

With her history of type 2 diabetes, hypertension, and obesity; new diagnosis of DKD; and the associated increased risk of HF, early treatment with a sodium–glucose cotransporter 2 (SGLT2) inhibitor would have been an ideal choice for the management of this patient’s type 2 diabetes and comorbidities. Four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) have been approved by the U.S. Food and Drug Administration (FDA) for glycemic control, and their cardiorenal benefits have been demonstrated in randomized control trials (RCTs) (Table 1) (7,36–44). Based on these trial results, the FDA approved dapagliflozin for use in patients with either HF with reduced ejection fraction (HFrEF) (45) or CKD at risk for progression (46), regardless of their type 2 diabetes status. Furthermore, the FDA recently (August 2021) approved empagliflozin for use in patients with HFrEF (47).

Accordingly, SGLT2 inhibitors are included in the ADA’s *Standards of Medical Care in Diabetes—2022* (32) and in particular were recommended for people with type 2 diabetes and established atherosclerotic CVD (ASCVD) or CVD risk factors, HFrEF, or CKD (32). SGLT2 inhibitors were also included in guidelines from the American College of Cardiology (ACC) in 2020 (48), the European Society of Cardiology (ESC) in 2021 (10), and KDIGO in 2020 (30) for the treatment of type 2 diabetes with CKD and/or HF.

Another class of glucose-lowering therapies, glucagon-like peptide 1 (GLP-1) receptor agonists, have also been shown in RCTs to significantly reduce cardiovascular events in people with type 2 diabetes and may slow progression of CKD (50–52). GLP-1 receptor agonists are therefore also included in the ADA’s 2022 Standards of Care for people with type 2 diabetes and established ASCVD or CVD risk factors (32) or in people with CKD and increased risk for cardiovascular events (25).

Mineralocorticoid receptor antagonists (MRAs) may also be used with caution in patients with HF and type 2 diabetes to reduce the risk of mortality from HF (53–55). The FDA recently (July 2021) approved a third-generation MRA, finerenone, for the treatment of people with CKD associated with type 2 diabetes (56). Despite these new treatment options, a significant burden of CKD and CVD still exists in people with type 2 diabetes (32).

CKD is an independent risk factor for hypoglycemia (57), and concomitant use of SGLT2 inhibitors with sulfonylureas or insulin may increase the risk of hypoglycemia (58). In the case presented here, the patient’s diagnosis of DKD and continuation of glipizide may
### TABLE 1 Evidence of Cardiorenal Benefits of SGLT2 Inhibitors From Randomized Controlled Phase 3 Clinical Trials of SGLT2 Inhibitors Versus Placebo

| Study (N) | Trial Population | Primary End Point(s) | Hazard Ratio (95% CI) for SGLT2 Inhibitor Versus Placebo; P |
|-----------|------------------|----------------------|---------------------------------------------------------------|
| **Dapagliflozin** | | | |
| DECLARE-TIMI (N = 17,160) (36) | Patients aged ≥40 years with type 2 diabetes who had or were at risk for ASCVD | MACE (CV death, MI, or ischemic stroke) | 0.93 (0.84–1.03); 0.17 |
| | | Composite of death from CV causes or HHF | 0.83 (0.73–0.95); 0.005 |
| DAPA-HF (N = 4,744) (37) | Patients aged ≥18 years with NYHA class II–IV HF with LVEF ≤40%, with or without type 2 diabetes | Composite of worsening HF (HHF or urgent visit resulting in intravenous therapy for HF) or death from CV causes | 0.74 (0.65–0.85); <0.001 |
| DAPA-CKD (N = 4,304) (38) | Patients aged ≥18 years with CKD (eGFR 25–75 mL/min/1.73 m² and UACR 200–5,000 mg/g), with or without type 2 diabetes | Composite of sustained eGFR decline >50%, ESRD, or death from CV causes | 0.61 (0.51–0.72); <0.001 |
| **Canagliflozin** | | | |
| CANVAS (N = 10,142) (39) | Patients with type 2 diabetes who were either aged ≥30 years with a history of symptomatic ASCVD or aged ≥50 years at high risk for CVD | Composite of death from CV causes, nonfatal MI, or nonfatal stroke | 0.86 (0.75–0.97); <0.001 |
| CREDENCE (N = 4,401) (40) | Patients aged ≥30 years with type 2 diabetes and CKD (eGFR 30–90 mL/min/1.73 m² and UACR 300–5,000 mg/g) | Composite of ESRD, doubling of serum creatinine level, or death from renal or CV causes | 0.70 (0.59–0.82); <0.001 |
| **Empagliflozin** | | | |
| EMPA-REG OUTCOME (N = 7,020) (41) | Patients aged ≥18 years with type 2 diabetes at high risk for CV events | Composite of death from CV causes, nonfatal MI, or nonfatal stroke | 0.86 (0.74–0.99); 0.04 |
| EMPEROR-Reduced (N = 3,730) (42) | Patients aged ≥18 years with NYHA class II–IV HF with LVEF ≤40%, with or without type 2 diabetes | Composite of death from CV causes or HHF | 0.75 (0.65–0.86); <0.001 |
| EMPEROR-Preserved (N = 5,988) (43) | Patients aged ≥18 years with NYHA class II–IV HF with LVEF >40%, with or without type 2 diabetes | Composite of death from CV causes or HHF | 0.79 (0.69–0.90); <0.001 |
| **Ertugliflozin** | | | |
| VERTIS CV (N = 8,238) (44) | Patients aged ≥40 years with type 2 diabetes and established ASCVD | MACE (composite of death from CV causes, nonfatal MI, or nonfatal stroke) | 0.97 (0.85–1.11); <0.001 |

CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy; CV, cardiovascular; DAPA-CKD, A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease; DAPA-HF, Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; DECLARE-TIMI 58, Dapagliflozin Effect on Cardiovascular Events; EMPA-REG OUTCOME, BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; EMPEROR-Reduced, Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction; EMPEROR-Preserved, Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction; ESRD, end-stage renal disease; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MI, myocardial infarction; NYHA, New York Heart Association; VERTIS CV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease.
partly explain why an SGLT2 inhibitor was not prescribed. However, used alone in DKD, SGLT2 inhibitors are not associated with a higher risk of hypoglycemia (40), and the ADA’s Standards of Medical Care in Diabetes—2022 recommended use of SGLT2 inhibitors independent of A1C level (59).

Given the evidence for the benefits of SGLT2 inhibitors on renal outcomes and the lack of equivalent evidence for the use of sulfonylureas, discontinuation of glipizide in favor of treatment with an SGLT2 inhibitor should have been considered. Although not indicated for HF in this case, the positive effect on cardiovascular outcomes seen with SGLT2 inhibitors may have offered additional benefits for this patient, who was high risk for HF.

**Multidisciplinary Outpatient Management of Patients With Type 2 Diabetes and Cardiorenal Diseases**

*Why Is the Early Diagnosis of CKD and HF Important?*

Early diagnosis and management of CKD is important for delaying CKD progression and preventing adverse clinical outcomes. In individuals >40 years of age who are otherwise healthy, there is a decline in eGFR of \(\sim 1\) mL/min/1.73 m\(^2\) per year (60). In type 2 diabetes, an accelerated annual eGFR decline of 2–3 mL/min/1.73 m\(^2\) is often seen, even in those with relatively good glycemic control (A1C 6.5–7.0%) (61). Greater eGFR declines of 4–5 mL/min/1.73 m\(^2\) per year occur in patients with albuminuria levels \(\geq 900\) mg/g (38,40). Severity of CKD and degree of albuminuria are multipliers of risks for cardiovascular events, progression to end-stage renal disease, and both cardiovascular and all-cause death.

Early drug therapy may also slow disease progression and improve clinical outcomes in individuals with HF, reducing their risk of hospitalization for acute heart failure (HHF). Reducing HHF is key in reducing cardiovascular-related mortality, because repeated HHF is a strong predictor of both all-cause and cardiovascular death (62). Often unrecognized, but critically important, the risk of cardiovascular death is additive, increasing with each subsequent HHF (63).

*What Role Does Nutrition Play in the Management of Type 2 Diabetes and Cardiorenal Disease?*

Guidelines from KDIGO for patients with type 2 diabetes and CKD and from the ACC/American Heart Association (AHA) for those with HF and/or type 2 diabetes recommend a balanced diet that is high in vegetables, fiber, legumes, nuts, plant-based protein, unsaturated fats, and whole grains and limited in phosphorus (30,64). In line with recommendations from the World Health Organization, the KDIGO guidelines also suggest a daily dietary protein intake of 0.8 g/kg body weight, a daily salt intake of \(< 5.0\) g, and at least 150 minutes of moderate-intensity physical activity per week (30,65). Importantly, diet should be tailored to each patient and result from shared decision-making between accredited dietitian nutritionists, diabetes educators, counselors, and other community health care practitioners (30).

*What Was the Rationale for This Patient’s Treatment Regimen?*

**Why Was the Patient Sent Home on Metformin?**

Previously, it was suggested that metformin use in patients with HF may increase the risk of lactic acidosis, but subsequent research has not supported this relationship, and the boxed warning for metformin was removed in 2016 (66,67). The use of metformin has also been associated with hypoglycemia in patients with CKD, but guidelines now state that a dose of 1,000 mg metformin can be used safely in patients with an eGFR of \(\geq 30–45\) mL/min/1.73 m\(^2\) (30,59,68). Given that the patient in this case had an eGFR of 60 mL/min/1.73 m\(^2\) (stage 2 CKD), continued treatment with metformin was in line with guidelines. Furthermore, metformin use has been shown to be associated with better short- and long-term prognosis and reduced mortality in patients with HF and type 2 diabetes, suggesting that continued treatment with metformin in this case may be beneficial beyond glycemic control (66).

**Should the Patient Have Been Prescribed a β-Blocker on Discharge?**

Current ESC guidelines acknowledge that there is limited evidence for effective treatment of HFmrEF owing to a lack of dedicated RCTs in this group and therefore do not make strong recommendations for specific treatments. The use of β-blockers in patients with HFmrEF can be considered, particularly in patients with additional indications for a β-blocker (10). In this case, there was not a clear indication for the prescription of a β-blocker.

**Why Was the Patient Not Prescribed an SGLT2 Inhibitor on Discharge?**

Given her medical history and inpatient diagnosis, this patient was an ideal candidate for treatment with an SGLT2 inhibitor at discharge. However, despite the clear benefits of SGLT2 inhibitors in reducing adverse
renal and cardiovascular outcomes, there remains clinical inertia for prescription of SGLT2 inhibitors in type 2 diabetes and concomitant CKD and/or HF. This inertia is compounded by concerns regarding how to initiate the treatment safely in an inpatient setting (69). Trials testing SGLT2 inhibitors in an inpatient setting, including after a myocardial infarction and/or acute HF, are ongoing. In addition, access to SGLT2 inhibitors may vary among hospitals depending on whether they are available on inpatient formularies, which may also limit their use. Concerns remain regarding the risk of acute decline in eGFR and acute kidney injury (AKI) because of the renal mode of action of SGLT2 inhibitors. On the contrary, RCTs examining renal outcomes have shown that rates of AKI are reduced among those receiving SGLT2 inhibitors compared with placebo (70).

In this case, there may have been concerns about excessive diuresis and a perceived risk of natriuresis in the patient by combining an SGLT2 inhibitor with furosemide, because it has been suggested that the diuretic effect is a potential mechanism underlying the cardiorenal benefits of SGLT2 inhibitors (7). The RECEDE-CHF (SGLT2 Inhibition in Combination With Diuretics in Heart Failure) trial (71), a randomized, double-blind study of individuals with HF and type 2 diabetes who received a loop diuretic with either 25 mg of empagliflozin or a placebo, revealed that SGLT2 inhibition resulted in a sustained additional urine volume of about 500 mL/day throughout the 6-week trial. A 24-hour urinary sodium excretion comparison between the empagliflozin and placebo groups (71,72) suggested that concomitant treatment with a loop diuretic did not place patients at increased risk of an electrolyte imbalance. A subgroup analysis also showed that the benefits of SGLT2 inhibitors in patients with HF were similar with and without diuretic use (71).

**Why Was the Hydrochlorothiazide Discontinued at Discharge?**

Although combination therapies of loop and thiazide diuretics may be beneficial in individuals with diuretic-resistant edema, intensive treatment can lead to electrolyte disorders through sequential nephron blocking, increasing the risk of hypokalemia, hyponatremia, and hypotension (73,74). With this patient’s diagnosis of HF and pulmonary edema and her eGFR of 60 mL/min/1.73 m², it is appropriate that hydrochlorothiazide was discontinued upon initiation of furosemide.

**What Is the Role of PCCs in the Follow-Up Care of Patients With Cardiorenal Disease and Type 2 Diabetes?**

**Who Should Provide the Patient’s Follow-Up Care?**

AHA guidelines recommend a multidisciplinary approach to the management of individuals with type 2 diabetes and cardiorenal disease, with regular glucose, lipid, and blood pressure monitoring (7). However, patients often only have access to specialized care at a relatively late stage in their disease trajectory. PCCs are in a unique position to facilitate the early diagnosis of cardiorenal disease in individuals with type 2 diabetes, in addition to playing a key role in establishing their treatment regimen.

Primary care practices have an opportunity to coordinate the multidisciplinary management of these patients to ensure comprehensive care (7), in which the expertise of each specialty is maximized and type 2 diabetes, HF, and CKD are not treated as discrete problems. A team approach with input from nephrologists, cardiologists, endocrinologists, diabetes educators, social workers, and community support works best to manage individuals as outpatients. It is vital that a good chain of communication be established between PCCs and other specialists and that any changes to a patient’s monitoring or treatment plan be made clear to the multidisciplinary team. Timely referrals to relevant specialists when appropriate are also key (Figure 2) (32,75).

**What Treatment(s) Should Have Been Prescribed to This Individual as an Outpatient?**

In line with recommendations from both the American Academy of Clinical Endocrinology and the ADA, this patient would have been an ideal candidate for outpatient therapy with an SGLT2 inhibitor (59,76). The renal and cardiovascular benefits of SGLT2 inhibitors have led health care professionals to question who should be responsible for their prescription—specialists such as nephrologists, cardiologists, and endocrinologists or PCCs such as primary care physicians (internal medicine and family medicine), primary care nurse practitioners, and primary care physician assistants? In a multidisciplinary team, not all providers feel comfortable prescribing a treatment originally indicated for use as a glucose-lowering therapy, despite one SGLT2 inhibitor (dapagliflozin) now having an independent indication for the treatment of CKD (46) and HFrEF (45) (FDA approvals granted in April 2021 and May 2020, respectively) in patients with and without type 2 diabetes (77).
Experience and comfort with using these medications is growing, but despite the outcomes data supporting renal and cardiovascular benefits, the uptake of SGLT2 inhibitors has been slow in clinical practice. More needs to be done to ensure that all clinicians are familiar and comfortable with prescribing SGLT2 inhibitors and that cardiologists and nephrologists understand the renal and cardiovascular benefits of SGLT2 inhibitors. Although responsibility should be shared between all clinicians, PCCs have a vital part to play in the timely prescription of SGLT2 inhibitors and the management and mitigation of potential side effects associated with their use. For example, SGLT2 inhibitor use is associated with an elevated risk of genital mycotic infections and may be associated with a slightly elevated risk of urinary tract infections (78). PCCs can play a role in mitigating these side effects by educating patients about appropriate hygiene. A transient decrease in eGFR of ~2–5 mL/min/1.73 m² may be observed within the first 2–4 weeks after SGLT2 inhibitor initiation (79–81). Although it is important for PCCs to be aware of this small decline in kidney function, this acute eGFR dip is largely reversible and does not have a negative effect on long-term cardiovascular and renal outcomes. SGLT2 inhibitor use may also cause transient volume depletion in the first 1–2 weeks of treatment (82), although AKI resulting from this drop can be prevented by volume status monitoring. Furthermore, there may be an increased risk of euglycemic diabetic ketoacidosis associated with SGLT2 inhibitor use, particularly in patients with restricted carbohydrate intake (83). However, these events are rare. It is important for PCCs to be aware of these potentially severe adverse events so they can monitor patients appropriately and make timely diagnoses should these events occur.

In addition to an SGLT2 inhibitor, it was appropriate that the patient in this case continue to receive treatment with an ACE inhibitor, but it should have been increased to the maximal tolerated dose (10,30), as used in studies of SGLT2 inhibitors for HF and CKD. Annual lipid profile screening and, if necessary, treatment with lipid-lowering medications per ACC/AHA guidelines (64,84,85) may also have been beneficial in this patient, given her HF diagnosis. Ideally, a full ischemic evaluation with a stress test, cardiac computed tomography scan, or coronary angiogram should have been considered. A summary of the case presentation and opportunities for improved treatment of this patient is provided in Figure 1.
What Are the Barriers to Multidisciplinary Management of Patients With Type 2 Diabetes and Cardiorenal Diseases, and How Can They Be Overcome?

Clinical inertia, or the failure to intensify treatment in a timely manner, is likely a major barrier to the multidisciplinary management of individuals with type 2 diabetes and concomitant CKD and/or HF. Clinicians and patients may be hesitant to make changes to treatment plans that appear to be working, and clinicians may overestimate how many of their patients are reaching treatment targets (31).

A lack of communication between clinicians may also prevent continuous multidisciplinary care, and more needs to be done to facilitate communication channels between clinicians, including regular contact between members of a multidisciplinary care team centered around a shared responsibility for facilitating treatment. Improving communication between clinicians and patients regarding the treatment plan is also important; regular review of medications at each visit will help to decrease the risk of polypharmacy (7).

Motivational interviewing may be beneficial for improving adherence to a complex shared treatment plan by engaging patients and establishing their motivations for change (87). As part of this effort, social determinants of health, particularly financial limitations that are prevalent in patients with type 2 diabetes, HF, and CKD, must be considered when making treatment decisions, because these can significantly affect patients’ ability to adhere to treatment (31).

Conclusion

In this clinical vignette, we presented a patient with a history of hypertension, obesity, and type 2 diabetes who was hospitalized for breathlessness and discharged with a diagnosis of DKD and HFmrEF. This case is representative of many seen in clinical practice, in which earlier diagnosis of cardiorenal conditions may have prevented or delayed hospitalization.

The case highlights the key role PCCs should play in each stage of a patient’s journey, from the early diagnosis of cardiorenal conditions (requiring improved risk factor recognition) to coordination of multidisciplinary care upon hospital discharge. It also shows that establishing good cross-team clinical guidelines and clear communication channels is essential for ensuring continuity of care.

In conclusion, early screening for cardiorenal conditions, adherence to current treatment guidelines, and management of patients across multidisciplinary teams provide vital opportunities to reduce the morbidity, mortality, and hospitalization rates of individuals with type 2 diabetes and cardiorenal diseases. Such efforts could reduce associated health care costs and improve patients’ health-related quality of life.

FUNDING

Medical writing and editorial support for this manuscript was provided by Katie Willetts, PhD, and Paul Williams of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.

DUALITY OF INTEREST

P.R.K. has received honoraria from AstraZeneca. M.A.C. has received research support from AstraZeneca. C.W.M. has held positions on speaker bureaus and an advisory board for AstraZeneca.

AUTHOR CONTRIBUTIONS

All authors contributed to the manuscript conceptualization, clinical content, manuscript writing, and discussion. All authors critically reviewed the manuscript and approved its final version for submission. P.R.K. is the guarantor of this work and, as such, had full access to all the data presented and takes responsibility for the integrity of the data and the accuracy of the data analysis.

REFERENCES

1. Virani SS, Alonso A, Benjamin EJ, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 2020;141: e139–e596
2. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018;17:83–100
3. Dei Cas A, Khan SS, Butler J, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015;3:136–145
4. Rangaswami J, Bhalla V, Blair JEA, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840–e878
5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527–1539
6. Banerjee S, Panas R. Diabetes and cardiorenal syndrome: understanding the “triple threat.” Hellenic J Cardiol 2017;58:342–347
7. Rangaswami J, Bhalla V, de Boer IH, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation 2020;142:e265–e286

8. Cherney DZI, Repetto E, Wheeler DC, et al. Impact of cardio-renal-metabolic comorbidities on cardiovascular outcomes and mortality in type 2 diabetes mellitus. Am J Nephrol 2020;51:74–82

9. Zareini B, Blanche P, D’Souza M, et al. Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study. Circ Cardiovasc Qual Outcomes 2020;13:e006260

10. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726

11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017;12:2032–2045

12. Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res 2016;118:1771–1785

13. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab 2016;20:546–551

14. Duca L, Sippl R, Snell-Bergeon JK. Is the risk and nature of CVD the same in type 1 and type 2 diabetes? Curr Diab Rep 2013;13:350–361

15. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34

16. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614–1619

17. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res 2019;124:121–141

18. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–2673

19. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol 2018;71:339–351

20. Aljohar A, Alhabib KF, Kashour T, et al. The prognostic impact of hyperglycemia on clinical outcomes of acute heart failure: insights from the heart function assessment registry trial in Saudi Arabia. J Saudi Heart Assoc 2018;30:319–327

21. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660–671

22. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007;56:2457–2466

23. Costantini S, Paneni F, Mitchell K, et al. Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66sc. Int J Cardiol 2018;268:179–186

24. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab 2012;15:805–812

25. American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S175–S184

26. Shlipak MG, Tummalapalli SL, Boulware LE, et al.; Conference Participants. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 2021;99:34–47

27. Evans M, Morgan AR, Patel D, et al. Risk prediction of the diabetes missing million: identifying individuals at high risk of diabetes and related complications. Diabetes Ther 2021;12:87–105

28. Mueller C, McDonald K, de Boer RA, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731

29. Modin D, Andersen DM, Biering-Sørensen T. Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides? Echo Res Pract 2018;5:R65–R79

30. de Boer IH, Caramori ML, Chan JCN, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98(Suppl. 4):S1–S115

31. American Diabetes Association. ADA’s Standards of Medical Care in Diabetes. Clin Diabetes 2021;39:128

32. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S144–S174

33. Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL. Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Heart Assoc 2018;7:e009992

34. Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J 2014;14:616–632

35. McAlister FA, Eurban DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008;10:703–708
36. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357
37. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008
38. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–1446
39. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
40. Perkovic V, Jardine MJ, Neal B, et al.; CREDiT Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306
41. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagli- flozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
42. Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–1424
43. Anker SD, Butler J, Filippatos G, et al.; EMPEROR-Preserved Trial Investigators. Empagli- flozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461
44. Cannon CP, Pratley R, Dagogo-Jack S, et al.; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383:1425–1435
45. U.S. Food and Drug Administration. FDA approves new treatment for a type of heart failure. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure. Accessed 20 September 2021
46. U.S. Food and Drug Administration. FDA approves treatment for chronic kidney disease. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease. Accessed 20 September 2021
47. Boehringer Ingelheim. Jardiance (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction. Available from https://www.boehringer-ingelheim.com/press-release/reduced-heart-failure-treatment-approval-europe. Accessed 20 September 2021
48. Das SR, Everett BM, Birkhiser KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020;76:1117–1145
49. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:221–228
50. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semiaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844
51. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322
52. Mann JFE, Ørsted DD, Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839–848
53. Cooper LB, Lippmann SJ, Greiner MA, et al. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc 2017;6:e006540
54. Chen MD, Dong SS, Cai NY, et al. Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:28
55. Lytvy N, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid antagonism and diabetic kidney disease. Curr Diab Rep 2019;19:19
56. U.S. Food and Drug Administration. FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease. Accessed 20 September 2021
57. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121–1127
58. van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 2018;41:1543–1556
59. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S125–S143
60. Nojima J, Meguro S, Ohkawa N, Furukoshi M, Kawai T, Itoh H. One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:746–754
61. Warren B, Rebolch CM, Sang Y, et al. Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the Atherosclerosis Risk in Communities study. Diabetes Care 2018;41:1646–1653
62. Lin AH, Chin JC, Sicignano NM, Evans AM. Repeat hospitalizations predict mortality in patients with heart failure. Mil Med 2017;182:e1932–e1937

63. Lahoz R, Fagan A, McSharry M, Proudfoot C, Corda S, Studer R. Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. ESC Heart Fail 2020;7:1688–1699

64. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:e177–e232

65. Food and Agriculture Organization of the United Nations, World Health Organization, United Nations University. Protein and amino acid requirements in human nutrition: report of a joint FAO/WHO/UNU expert consultation. Available from https://apps.who.int/iris/handle/10665/24534. Accessed 20 September 2021

66. Eerich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395–402

67. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Metformin use in patients with historical contraindications or precautions: appendix A FDA safety alert for metformin. Available from https://www.ncbi.nlm.nih.gov/books/NBK409379. Accessed 20 September 2021

68. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431–1437

69. Mazer CD, Arnaout A, Connelly KA, et al. Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls. Diabetes Care 2011;34:1431

70. Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2 inhibitors: a systematic review and meta-analysis. PLoS Med 2016;13:e1002098

71. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation 2020;142:1713–1724

72. Scholtes RA, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 2020;97:597–602

73. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010;56:1527–1534

74. National Institute for Health and Care Excellence. Diuretics. Available from https://bnf.nice.org.uk/treatment-summary/diuretics.html. Accessed 20 September 2021

75. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S185–S194

76. Garber AJ, Handselman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2020 executive summary. Endocr Pract 2020;26:107–139

77. Vardeny O, Vaguganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail 2019;7:169–172

78. Johansen ME, Argyropoulos C. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use sodium glucose cotransporter 2 inhibitors is now. Clin Cardiol 2020;43:1376–1387

79. Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 2021;99:750–762

80. van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasoconstriction rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 2020;97:202–212

81. Heerspink HJL, Cherney D, Postmus D, et al.; DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int 2022;101:174–184

82. Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 [sodium-glucose linked transporter 2] inhibitors. Hypertension 2020;75:894–901

83. Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep 2020;7:17–19

84. American Heart Association. Heart-health screenings. Available from https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/heart-health-screenings. Accessed 20 September 2021

85. National Institute for Health and Care Excellence. Chronic heart failure in adults. Available from https://www.nice.org.uk/guidance/ng106/evidence/full-guideline-pdf-6538850029. Accessed 20 September 2021

86. Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther 2014;5:347–354

87. Rollnick S, Butler CC, Kinnersley P, Gregory J, Mash B. Motivational interviewing. BMJ 2010;340:c1900